Your English writing platform
Discover LudwigSuggestions(1)
Exact(22)
Gadgeel, S., Shaw, A. T., Barlesi, F., Crino, L., Yang, J. C., Dingemans, A. C. et al. Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.
Double-blinded studies were performed to examine the effects of intrastriatally transplanted human MSC/BDNF on disease progression in two strains of immune-suppressed HD transgenic mice: YAC128 and R6/2.
Logistic regression was used to model ROA incidence and progression in two ways.
The reasons for terminating chemotherapy were patients' decision in four patients, adverse events in three, and disease progression in two.
The reasons for terminating chemotherapy were adverse events in five patients (56 %) and disease progression in two (22%%).
The reason for not completing radiotherapy was disease progression in two patients and thrombocytopenia in one patient.
Similar(38)
In this review, we outline the origin of myofibroblasts, their general characteristics and functions during fibrosis progression in three major organs: liver, kidneys and lungs as well as in cancer.
Repetitive dosing in a cohort of 14 dogs, at the defined optimal dose, was well tolerated and led to objective tumor regression in two dogs (14%), stable disease in six (43%), and disease progression in six (43%) via Response Evaluation Criteria in Solid Tumors (RECIST).
Brain was the only site of disease progression in six of these patients.
The best response was partial response in four (16.7%) patients, stable disease in 17 (70.8%) and progression in three (12.5%).
We characterized in detail the disease expression and progression in eight dogs from age 2 to 16 months.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com